A nurse is teaching a client who has active pulmonary tuberculosis about management of medication for the disease. Which of the following statements is appropriate for the nurse to make?

Active tuberculosis is an infectious disease caused by Mycobacterium tuberculosis requiring combination chemotherapy to eradicate persistent bacilli and prevent multidrug resistance. Standard regimens utilize bactericidal agents like isoniazid and rifampin to achieve sterilization of infected tissues and prevent clinical relapse. Rationale: A. Monthly monitoring of kidney function is not a standard requirement for primary tuberculosis medications like isoniazid or rifampin, which are primarily hepatotoxic. While some aminoglycosides used for resistant cases affect renal status, the main concern for most patients is liver enzyme elevation. The nurse should focus on monitoring hepatic function and signs of jaundice instead of routine renal labs. B. Taking two or more medications is essential because Mycobacterium tuberculosis is highly prone to developing resistance if treated with monotherapy. Using a combination, such as the RIPE (rifampin, isoniazid, pyrazinamide, ethambutol) regimen, ensures that different bacterial populations and metabolic states are targeted simultaneously. This strategy is the cornerstone of preventing the emergence of multidrug-resistant tuberculosis strains during the long course of treatment. C. Treatment for active tuberculosis typically lasts 6 to 9 months, rather than 3 years, for drug-susceptible cases. Extending therapy to 3 years is not standard practice and could lead to significant toxicity and non-compliance issues. The nurse must provide an accurate timeline to the client to ensure they understand the necessity of completing the entire several-month course. D. Tuberculin skin tests are used for screening and diagnosis but are not useful for monitoring treatment progress in a patient already diagnosed with active disease. Once a skin test is positive, it will likely remain positive regardless of treatment success. Progress is instead monitored through sputum cultures, chest radiographs, and clinical improvement in symptoms like cough and fever.